JP6976947B2 - 自己免疫疾患の処置に有用なビピラゾリル誘導体 - Google Patents

自己免疫疾患の処置に有用なビピラゾリル誘導体 Download PDF

Info

Publication number
JP6976947B2
JP6976947B2 JP2018531127A JP2018531127A JP6976947B2 JP 6976947 B2 JP6976947 B2 JP 6976947B2 JP 2018531127 A JP2018531127 A JP 2018531127A JP 2018531127 A JP2018531127 A JP 2018531127A JP 6976947 B2 JP6976947 B2 JP 6976947B2
Authority
JP
Japan
Prior art keywords
mmol
formula
compound
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018531127A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019505491A (ja
Inventor
ボサナック，トッド
ベントツィーン，イェルク
バーク，マイケル・ジェイソン
フライアー，ライアン・マイケル
ラーソン，エリック・トーマス
マオ，ワン
マッキベン，ブライアン・パトリック
シェン，ユエ
ソリマンザデー，ファリバ
チャンツ，マット・アーロン
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2019505491A publication Critical patent/JP2019505491A/ja
Application granted granted Critical
Publication of JP6976947B2 publication Critical patent/JP6976947B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2018531127A 2015-12-16 2016-12-15 自己免疫疾患の処置に有用なビピラゾリル誘導体 Active JP6976947B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562268278P 2015-12-16 2015-12-16
US62/268,278 2015-12-16
US201662431008P 2016-12-07 2016-12-07
US62/431,008 2016-12-07
PCT/US2016/066799 WO2017106429A2 (en) 2015-12-16 2016-12-15 Heteroaromatic compounds as btk inhibitors

Publications (2)

Publication Number Publication Date
JP2019505491A JP2019505491A (ja) 2019-02-28
JP6976947B2 true JP6976947B2 (ja) 2021-12-08

Family

ID=58737849

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018531127A Active JP6976947B2 (ja) 2015-12-16 2016-12-15 自己免疫疾患の処置に有用なビピラゾリル誘導体

Country Status (31)

Country Link
US (6) US9975882B2 (zh)
EP (1) EP3390390B1 (zh)
JP (1) JP6976947B2 (zh)
KR (1) KR20180095655A (zh)
CN (1) CN108368086B (zh)
AU (1) AU2016370743B2 (zh)
BR (1) BR112018011969B1 (zh)
CA (1) CA3005268C (zh)
CL (1) CL2018001569A1 (zh)
CO (1) CO2018005954A2 (zh)
CY (1) CY1124749T1 (zh)
DK (1) DK3390390T3 (zh)
EA (1) EA034561B1 (zh)
ES (1) ES2897910T3 (zh)
HK (1) HK1256795A1 (zh)
HR (1) HRP20211845T1 (zh)
HU (1) HUE056877T2 (zh)
IL (1) IL259281B (zh)
LT (1) LT3390390T (zh)
MX (1) MX2018007333A (zh)
MY (1) MY197440A (zh)
PE (1) PE20181074A1 (zh)
PH (1) PH12018501248A1 (zh)
PL (1) PL3390390T3 (zh)
PT (1) PT3390390T (zh)
RS (1) RS62525B1 (zh)
SA (1) SA518391864B1 (zh)
SG (1) SG11201804890TA (zh)
SI (1) SI3390390T1 (zh)
TW (1) TWI726017B (zh)
WO (1) WO2017106429A2 (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150040292A (ko) 2012-08-10 2015-04-14 베링거 인겔하임 인터내셔날 게엠베하 브루톤 티로신 키나제 (ｂｔｋ) 억제제로서의 헤테로방향족 화합물
AU2016373530B2 (en) 2015-12-16 2021-01-21 Loxo Oncology, Inc. Compounds useful as kinase inhibitors
HRP20211845T1 (hr) * 2015-12-16 2022-03-04 Boehringer Ingelheim International Gmbh Derivati bipirazolila korisni za liječenje autoimunih bolesti
WO2017123695A1 (en) 2016-01-13 2017-07-20 Boehringer Ingelheim International Gmbh Isoquinolones as btk inhibitors
JP7166331B2 (ja) * 2017-08-01 2022-11-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 中間体化合物及び方法
CA3224949A1 (en) 2018-07-31 2020-02-06 Loxo Oncology, Inc. Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
US20220175772A1 (en) * 2019-05-23 2022-06-09 Novartis Ag Methods of treating sjogren's syndrome using a bruton's tyrosine kinase inhibitor
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2022140246A1 (en) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
WO2023110936A1 (en) 2021-12-14 2023-06-22 Netherlands Translational Research Center Holding B.V Reversible macrocyclic kinase inhibitors
WO2023110970A1 (en) 2021-12-14 2023-06-22 Netherlands Translational Research Center Holding B.V Macrocyclic btk inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9608435D0 (en) 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
JP4739632B2 (ja) * 2000-02-05 2011-08-03 バーテックス ファーマシューティカルズ インコーポレイテッド Ｅｒｋのインヒビターとして有用なピラゾール組成物
CA2451981C (en) 2001-08-13 2012-02-21 Janssen Pharmaceutica N.V. 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity
US7307097B2 (en) 2001-09-27 2007-12-11 Smithkline Beechman Corporation Chemical compounds
FR2881426B1 (fr) 2005-02-03 2007-03-30 Aventis Pharma Sa Pyrolles et imidazoles substitues, compositions les contenant, procede de frabrication et utilisation
EP2007732B1 (en) 2006-04-11 2011-11-23 Vertex Pharmaceuticals, Inc. Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases
EP2081435B1 (en) 2006-09-22 2016-05-04 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
JP5347202B2 (ja) 2007-03-28 2013-11-20 ファーマサイクリックス，インク． ブルトンチロシンキナーゼインヒビター
AU2009275988B2 (en) 2008-07-29 2014-03-27 Universite De Liege A genetic marker test for Brachyspina and fertility in cattle
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
CA2750935A1 (en) 2009-01-30 2010-08-12 Millennium Pharmaceuticals, Inc. Heteroaryls and their use as pi3k inhibitors
US8907098B2 (en) 2009-12-17 2014-12-09 Merck Patent Gmbh Inhibitors of sphingosine kinase
PL2578585T3 (pl) 2010-05-31 2017-01-31 Ono Pharmaceutical Co., Ltd. Pochodna purynonu jako inhibitor kinazy btk
WO2012021615A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
JP5985658B2 (ja) * 2012-01-31 2016-09-06 ナンジン アルゲン ファルマ カンパニー リミテッドＮａｎｊｉｎｇ Ａｌｌｇｅｎ Ｐｈａｒｍａ Ｃｏ． Ｌｔｄ． ブルトンチロシンキナーゼ阻害薬としての環状分子
KR20150040292A (ko) * 2012-08-10 2015-04-14 베링거 인겔하임 인터내셔날 게엠베하 브루톤 티로신 키나제 (ｂｔｋ) 억제제로서의 헤테로방향족 화합물
MX2015005422A (es) 2012-11-02 2015-08-05 Pfizer Inhibidores de la tirosina-quinasa de bruton.
CN103848810A (zh) 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
JP6403751B2 (ja) * 2013-03-14 2018-10-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ５−チアゾールカルボキサミン誘導体及びｂｔｋ阻害剤としてのその使用
US9828364B2 (en) 2014-01-29 2017-11-28 Boehringer Ingelheim International Gmbh Pyrazole compounds as BTK inhibitors
HRP20211845T1 (hr) * 2015-12-16 2022-03-04 Boehringer Ingelheim International Gmbh Derivati bipirazolila korisni za liječenje autoimunih bolesti

Also Published As

Publication number Publication date
IL259281A (en) 2018-07-31
AU2016370743A1 (en) 2018-05-24
EP3390390B1 (en) 2021-09-01
WO2017106429A2 (en) 2017-06-22
CA3005268A1 (en) 2017-06-22
PL3390390T3 (pl) 2022-01-24
EA034561B1 (ru) 2020-02-20
BR112018011969B1 (pt) 2023-02-23
HK1256795A1 (zh) 2019-10-04
TW201731838A (zh) 2017-09-16
CY1124749T1 (el) 2022-07-22
PT3390390T (pt) 2021-11-18
BR112018011969A2 (pt) 2018-12-04
ES2897910T3 (es) 2022-03-03
CL2018001569A1 (es) 2018-10-05
CN108368086A (zh) 2018-08-03
CO2018005954A2 (es) 2018-07-10
US9975882B2 (en) 2018-05-22
CN108368086B (zh) 2021-01-08
DK3390390T3 (da) 2021-12-06
US20210009567A1 (en) 2021-01-14
JP2019505491A (ja) 2019-02-28
AU2016370743B2 (en) 2020-11-26
RS62525B1 (sr) 2021-11-30
PE20181074A1 (es) 2018-07-04
HRP20211845T1 (hr) 2022-03-04
SA518391864B1 (ar) 2021-12-13
EA201891399A1 (ru) 2019-01-31
US20180222893A1 (en) 2018-08-09
US20170174663A1 (en) 2017-06-22
US20190092759A1 (en) 2019-03-28
US20180030037A1 (en) 2018-02-01
KR20180095655A (ko) 2018-08-27
MY197440A (en) 2023-06-19
MX2018007333A (es) 2018-08-24
EP3390390A2 (en) 2018-10-24
IL259281B (en) 2021-04-29
SG11201804890TA (en) 2018-07-30
CA3005268C (en) 2024-04-30
WO2017106429A3 (en) 2017-08-17
PH12018501248A1 (en) 2019-01-28
SI3390390T1 (sl) 2021-12-31
HUE056877T2 (hu) 2022-03-28
US20200055843A1 (en) 2020-02-20
TWI726017B (zh) 2021-05-01
LT3390390T (lt) 2021-11-25

Similar Documents

Publication Publication Date Title
JP6976947B2 (ja) 自己免疫疾患の処置に有用なビピラゾリル誘導体
JP6348492B2 (ja) ブルトン型チロシンキナーゼ（ｂｔｋ）阻害剤としてのヘテロ芳香族化合物
JP6495886B2 (ja) Ｂｔｋ阻害剤としての複素環式芳香族化合物
ES2477878T3 (es) Compuestos y composiciones de 5-(4-(aloalcoxi)fenil)pirimidin-2-amina como inhibidores de quinasas
TWI534145B (zh) 四氫吡啶并嘧啶衍生物
JP6916185B2 (ja) Ｂｔｋ阻害剤としてのイソキノロン類
JP6486954B2 (ja) Ｂｔｋ阻害剤としてのピラゾール化合物
JP5538555B2 (ja) ピラゾロピリミジン化合物及びｐｄｅ１０阻害剤としてのその使用
KR102607934B1 (ko) 바닌 억제제로서의 헤테로방향족 화합물
JP2023051962A (ja) ９，１０，１１，１２－テトラヒドロ－８ｈ－［１，４］ジアゼピノ［５’，６’：４，５］チエノ［３，２－ｆ］キノリン－８－オン化合物およびその使用
JP2019503389A (ja) Ｐｄｅ１阻害剤
JP6403751B2 (ja) ５−チアゾールカルボキサミン誘導体及びｂｔｋ阻害剤としてのその使用
WO2012044090A2 (ko) 단백질 키나제 억제 활성을 갖는 신규한 아미노퀴나졸린 화합물
JP2013060438A (ja) ピラゾロピリミジン化合物及びｐｄｅ１０阻害剤としてのその使用
BR102016029685A2 (pt) compostos heteroaromáticos como inibidores de btk

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191209

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210219

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210518

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210913

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210913

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20211001

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20211005

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211102

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211110

R150 Certificate of patent or registration of utility model

Ref document number: 6976947

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150